VolitionRX (NYSEAMERICAN:VNRX) Posts Quarterly Earnings Results, Misses Expectations By $0.28 EPS

Posted by Francis Steltz on Aug 14th, 2026

VolitionRX (NYSEAMERICAN:VNRX – Get Free Report) released its quarterly earnings data on Thursday. The medical research company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.28), FiscalAI reports. The business had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.41 million.

VolitionRX Stock Performance

Shares of NYSEAMERICAN VNRX traded down $0.10 during mid-day trading on Friday, reaching $0.53. The company’s stock had a trading volume of 877,843 shares, compared to its average volume of 473,494. The stock has a market capitalization of $4.58 million, a P/E ratio of -0.13 and a beta of 1.16. VolitionRX has a 1-year low of $0.54 and a 1-year high of $15.10. The stock has a 50-day moving average of $1.16 and a two-hundred day moving average of $2.76.

Analysts Set New Price Targets

Several research firms have issued reports on VNRX. D. Boral Capital reiterated a “hold” rating on shares of VolitionRX in a research note on Monday, April 20th. Maxim Group restated a “buy” rating and set a $4.00 price objective on shares of VolitionRX in a research note on Thursday, June 18th. Citigroup downgraded VolitionRX to a “hold” rating in a research note on Monday, April 20th. Finally, Benchmark reaffirmed a “hold” rating on shares of VolitionRX in a report on Tuesday, June 2nd. Two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $28.00.

View Our Latest Analysis on VNRX

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Armistice Capital LLC raised its stake in VolitionRX by 10.4% during the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after purchasing an additional 887,351 shares during the period. Citadel Advisors LLC increased its stake in VolitionRX by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after purchasing an additional 135,775 shares during the period. Squarepoint Ops LLC purchased a new position in VolitionRX in the 4th quarter valued at approximately $34,000. Jane Street Group LLC acquired a new stake in shares of VolitionRX in the fourth quarter valued at $28,000. Finally, Geode Capital Management LLC boosted its stake in shares of VolitionRX by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after buying an additional 85,816 shares during the period. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRX

(Get Free Report)

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.